Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 7/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.45 |
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674300 | 0.90 | CTSL (0.50) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7357728 | 0.90 | CTSL (0.43) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7661515 | 0.89 | CCNE1 (0.54) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7673595 | 0.88 | KDM4E (0.45) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7667689 | 0.88 | KCNH3 (0.46) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7674302 | 0.87 | PDGFRA (0.44) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7672226 | 0.87 | CDK1 (0.45) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7671239 | 0.87 | PDGFRA (0.43) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7666303 | 0.87 | CTSL (0.43) | CTSLCDK1PDGFRACCNE1CDK2 | |
| SCHEMBL7663415 | 0.87 | PDGFRA (0.47) | CTSLCDK1PDGFRACCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | claimed |
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| WO-2000037471-A1 | 2-AMINO-9-ALKYLPURINES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |